Patrick James Orme

Array ( [id] => 6388976 [patent_doc_number] => 20100317720 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-16 [patent_title] => 'Methods and Compositions for the Treatment of Intestinal Conditions' [patent_app_type] => utility [patent_app_number] => 12/871366 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 14460 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0317/20100317720.pdf [firstpage_image] =>[orig_patent_app_number] => 12871366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9046832 [patent_doc_number] => 08541386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-24 [patent_title] => 'Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use' [patent_app_type] => utility [patent_app_number] => 12/859744 [patent_app_country] => US [patent_app_date] => 2010-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 60 [patent_no_of_words] => 28061 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12859744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8477876 [patent_doc_number] => 20120277283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications' [patent_app_type] => utility [patent_app_number] => 13/388630 [patent_app_country] => US [patent_app_date] => 2010-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 19236 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13388630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5978280 [patent_doc_number] => 20110071209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-24 [patent_title] => 'RNAi Modulation of the RHO-A Gene and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 12/847958 [patent_app_country] => US [patent_app_date] => 2010-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 24513 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0071/20110071209.pdf [firstpage_image] =>[orig_patent_app_number] => 12847958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6064928 [patent_doc_number] => 20110201798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-18 [patent_title] => 'THERAPEUTIC COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 12/838230 [patent_app_country] => US [patent_app_date] => 2010-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 93971 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0201/20110201798.pdf [firstpage_image] =>[orig_patent_app_number] => 12838230 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8277412 [patent_doc_number] => 20120171279 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-05 [patent_title] => 'STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES' [patent_app_type] => utility [patent_app_number] => 12/833625 [patent_app_country] => US [patent_app_date] => 2010-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 19075 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12833625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8336172 [patent_doc_number] => 20120202871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-09 [patent_title] => 'CATIONIC LIPIDS AND METHODS FOR THE DELIVERY OF THERAPEUTIC AGENTS' [patent_app_type] => utility [patent_app_number] => 13/381872 [patent_app_country] => US [patent_app_date] => 2010-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 76664 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13381872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8797094 [patent_doc_number] => 08435961 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-05-07 [patent_title] => 'Methods and compositions for increasing the activity of inhibitory RNA' [patent_app_type] => utility [patent_app_number] => 12/821967 [patent_app_country] => US [patent_app_date] => 2010-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 34846 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12821967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8114771 [patent_doc_number] => 08158601 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-17 [patent_title] => 'Lipid formulation' [patent_app_type] => utility [patent_app_number] => 12/813448 [patent_app_country] => US [patent_app_date] => 2010-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 56002 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 7 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/158/08158601.pdf [firstpage_image] =>[orig_patent_app_number] => 12813448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6351367 [patent_doc_number] => 20100249215 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-09-30 [patent_title] => 'Oligomeric Compounds And Compositions For Use In Modulation Of Pri-miRNAs' [patent_app_type] => utility [patent_app_number] => 12/797643 [patent_app_country] => US [patent_app_date] => 2010-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27466 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0249/20100249215.pdf [firstpage_image] =>[orig_patent_app_number] => 12797643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6148835 [patent_doc_number] => 20110020430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy' [patent_app_type] => utility [patent_app_number] => 12/785852 [patent_app_country] => US [patent_app_date] => 2010-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 16560 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020430.pdf [firstpage_image] =>[orig_patent_app_number] => 12785852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8095831 [patent_doc_number] => 20120083520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-05 [patent_title] => 'Ghrelin binding nucleic acids' [patent_app_type] => utility [patent_app_number] => 12/776377 [patent_app_country] => US [patent_app_date] => 2010-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 15987 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0083/20120083520.pdf [firstpage_image] =>[orig_patent_app_number] => 12776377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8164522 [patent_doc_number] => 08173615 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-05-08 [patent_title] => 'TRPM-2 antisense therapy' [patent_app_type] => utility [patent_app_number] => 12/753995 [patent_app_country] => US [patent_app_date] => 2010-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 16 [patent_no_of_words] => 4872 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/173/08173615.pdf [firstpage_image] =>[orig_patent_app_number] => 12753995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6128205 [patent_doc_number] => 20110086905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'Pseudocomplementary Oligonucleotides for Targeted Gene Therapy' [patent_app_type] => utility [patent_app_number] => 12/753016 [patent_app_country] => US [patent_app_date] => 2010-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 11970 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086905.pdf [firstpage_image] =>[orig_patent_app_number] => 12753016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8549300 [patent_doc_number] => 08324181 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-12-04 [patent_title] => 'Modulation of gene expression by oligomers targeted to chromosomal DNA' [patent_app_type] => utility [patent_app_number] => 12/750201 [patent_app_country] => US [patent_app_date] => 2010-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8497 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12750201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7744659 [patent_doc_number] => 20120022143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-01-26 [patent_title] => 'RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)' [patent_app_type] => utility [patent_app_number] => 13/256155 [patent_app_country] => US [patent_app_date] => 2010-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 42145 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0022/20120022143.pdf [firstpage_image] =>[orig_patent_app_number] => 13256155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8772421 [patent_doc_number] => 08426377 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-23 [patent_title] => 'iRNA agents with biocleavable tethers' [patent_app_type] => utility [patent_app_number] => 12/724267 [patent_app_country] => US [patent_app_date] => 2010-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 63136 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12724267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9530334 [patent_doc_number] => 08754201 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-06-17 [patent_title] => 'Therapeutic compositions' [patent_app_type] => utility [patent_app_number] => 12/721413 [patent_app_country] => US [patent_app_date] => 2010-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 147361 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12721413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7997373 [patent_doc_number] => 08080534 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-20 [patent_title] => 'Targeting PAX2 for the treatment of breast cancer' [patent_app_type] => utility [patent_app_number] => 12/708294 [patent_app_country] => US [patent_app_date] => 2010-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 60 [patent_no_of_words] => 29264 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/080/08080534.pdf [firstpage_image] =>[orig_patent_app_number] => 12708294 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8876031 [patent_doc_number] => 08470997 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-06-25 [patent_title] => 'Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization' [patent_app_type] => utility [patent_app_number] => 12/700851 [patent_app_country] => US [patent_app_date] => 2010-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7734 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12700851 [rel_patent_id] =>[rel_patent_doc_number] =>)